MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...

NCT05455320: Phase 3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide...

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...

SWOG - S2209 - Southwest Oncology Group NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma...

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma Study of ORIC-533 in Relapsed or Refractory Multiple...

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma This is a phase II study to determine the...

NCT05338047: Phase 2: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant This is a...

CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...

(SUCCESSOR-2) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib...

MASTER-2 NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2) NCT05231629: Phase 2:...

(MajesTEC-7) Newly diagnosed Multiple Myeloma NCT05552222: Phase 3: A Study to Compare Teclistamab in Combination With Daratumumab and...

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients NCT05463939: Teclistamab...

NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma NDMM RRMM The...

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...

NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell...

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...

NCT05338775: Phase 1: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor...

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell...

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell...

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding...

NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma This is a two-stage...

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel NCT05201781: Phase 4: A...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...

NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant...

DREAMM 12 Relapsed & Refractory Myeloma NCT04398745: Phase 1: A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma...

NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI) NCT04721002:...

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating...

NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem...

BMT CTN 1902 NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902 MM CAR-T to Upgrade Response BMT CTN 1902 This study is...

NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML NCT04887259: Phase 1/2: Trial of LAVA-051...

Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...

The INSURE Study 2701 The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM)...

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers The purpose of this study is to find out whether...

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma This is a Phase 1, open-label study to ...

1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory...

IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an...

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab NCT05053607: Real World...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies A Study to Evaluate...